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The purpose of the study is to evaluate the effect of iodine concentration of contrast material on 
detection of hepatocellular carcinoma with multi-slice spiral computed tomography (CT) by using 
double-arterial phase and portal venous phase enhanced scanning. Ninety-four (94) patients with 
hepatocellular carcinoma (HCC) were examined by hepatic plain CT and contrast-enhanced CT including 
early arterial phase (EAP), late arterial phase (LAP) and portal venous phase (PVP) scanning. Patients 
were randomized into two groups to receive Iopamidol 370 mg /ml (47 patients) and 300 mg /ml (47 
patients). The images were interpreted by two experienced radiologists together prospectively. The 
detection sensitivity for tumors of two size categories (2 or >2 cm) and iodine concentration groups 
were calculated and analyzed. A total of 318 lesions were detected with 86  2 cm in size and 232 >2 cm. 
For EAP and LAP, the sensitivity of Iopamidol 370 mg I/ml group was significantly higher than Iopamidol 
300 mg I/ml group for tumors  2 cm and all tumors. For PVP, there were no significant differences 
between groups. We concluded that high-iodine-concentration contrast material could improve the 
detection of HCC for EAP and LAP, especially for tumor  2 cm. 
 






With the use of multi-slice spiral CT (MSCT) widely, 
quadruple-phase CT consisting of early arterial, late 
arterial, portal venous and delayed phase on detection of 
hepatocellular carcinoma (HCC) has been recognized 
(Murakami et al., 2001, 2003, 2005; Pozzi et al., 2006; 
Schima et al., 2006; Ichikawa et al., 2002; Kajiya et al., 
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technique could improve the detection sensitivity of HCC, 
but also the contrast injection protocol such as contrast 
material dose, flow rate, iodine concentration of contrast 
material and timing could impact the detection of HCC 
(Iannaccone et al., 2005; Breen et al., 2004; Kudo, 2002). 
The effects of these factors had been studied in helical 
CT (Heiken et al., 1995; Hänninen et al., 2000; Kormano 
et al., 1983; Kim et al., 1998; Furuta et al., 2004; 
Marchianò et al., 2005; Behrendt et al., 2008; Sultana et 
al., 2003; Herman, 2004), but there were few researches 
that reported on the effect of iodine concentration of 
contrast material in which double-arterial phase scanning 
was used for detection of HCC (Pozzi et al., 2006; Awai 
et al., 2002; Yagyu et al., 2005). Pozzi et al. (2006) had 
used high-iodine-concentration contrast  agent  in  MSCT 




Table 1. Demographic and baseline characteristics in two groups. 
 
Parameter Group A (n = 47) Group B (n = 47) 
Demographic data   
Sex (men/women) 42/5 39/8 
Age (years), mean ± SD 51.7 ± 9.8 54.3 ± 10.6 
Weight (kg), mean ± SD 60.8 ± 11.7 58.6 ± 13.2 
BMI (kg/m2), mean ± SD 22.3 ± 4.5 20.6 ± 4.1 
Baseline liver disease characteristics  
Liver cirrhosis (%) 85.1 89.4 
Chronic hepatitis B (%) 48.9 57.4 
Chronic hepatitis C (%) 29.8 25.5 
Chronic alcoholic hepatitis (%) 21.3 17.0 
Iopamidol dose administered (mg) 33744.0 ± 6493.5 32523.0 ± 7326.0 
Iopamidol volume administered (ml)* 91.2 ± 17.6 108.4 ± 24.4 
 
Group A = Iopamidol 370 mg I/ml group; Group B = Iopamidol 300 mg I/ml group; BMI = body mass index. 




with double-arterial phase to detect HCC, but their results 
had no control group to be compared with and their 
conclusion had no statistical analysis to be based on.  
The purpose of this article is to evaluate the effect of 
iodine concentration of contrast material on detection of 
HCC with MSCT by using double-arterial phase and 
portal venous phase enhanced scanning with protocols of 
constant iodine load and constant iodine delivery rate.  
 
 




From September 2007 to July 2008, 126 patients who were 
suspected to have HCC clinically were assigned randomly to 
undergo MSCT of the liver with either of the two contrast material 
injections and scanning protocols. All patients were prospectively 
and randomly assigned into group A and group B by using a 
random-number table. Patients with pregnancy, lactation, 
administration of an iodinated contrast medium within the previous 
72 h, history of allergy to Iopamidol, manifest thyrotoxicosis, 
noncompensated cardiac insufficiency were excluded from this 
study. All patients gave their informed consents, and this study was 
approved by our Ethics Committee. 
Finally, ninety-four patients (81 men, 13 women, aged between 
29 and 91 years, mean age: 53 years) who were diagnosed as 
HCC (45 confirmed by operation, 18 confirmed by percutaneous 
biopsy and 31 confirmed by following up for a minimum of six 
months) were included in this study. All the 94 patients had chronic 
liver diseases (50 with type B hepatitis, 26 with type C hepatitis and 




CT protocol and contrast material infusion  
 
The CT scanner we used was Toshiba Aquilion 16 CT. To keep the 
total iodine dose and the iodine delivery rate constant for both 
protocols, patients of group A received Iopamidol (Bracco S.P.A., 
Italy) 370 mg I/ml (1.5 ml/kg body weight) at a flow rate of 4 ml/s 
and group B received Iopamidol (Bracco S.P.A., Italy) 300 mg I/ml 
(1.85 ml/kg body weight) at a flow rate of 4.9 ml/s, by means of a 
power injector (AD2002-CT, MEDEX, France) with 20-gauge 
intravenous catheters inserted into an antecubital vein. In the 94 
patients, there were 47 patients in group A and 47 patients in group 
B. Both groups were comparable regarding demographic and 
baseline liver disease characteristics (Table 1). A saline flush of 40 
ml followed the contrast medium injection, using the same injection 
rate as for the contrast medium. Bolus-tracking technique (Sure 
Start, Toshiba, Tokyo, Japan) was performed in order to optimize 
scan delays for early arterial phase (EAP) automatically. The mean 
injection-to-scan delay for EAP imaging was 23.5 s (range, 18 – 35 
s) for group A and 25.5 s (range, 16 – 38 s) for the group B. And 
the timing of the contrast-enhanced CT scans was uniformly 
defined: Late arterial phase (LAP) imaging started 15 s after 
initiation of EAP scanning; portal venous phase (PVP) imaging was 
initiated 50s after the start of the EAP. In scanning, patients were 
asked to hold their breath. The CT scanner detector configuration 
was 16 × 0. 5 mm. The tube voltage applied throughout all CT 
studies was 120 kVp. The tube current was adjusted according to 
patient characteristics (mean, 217 mA; range, 105 – 420 mA). In 
view center, axial images were reconstructed at an effective slice 





The images were interpreted by two radiologists (with 15 and 6 
years experience, respectively, as gastrointestinal radiologist) 
prospectively together. For each phase, the two readers recorded 
the details including size, location and the contrast pattern of 
hepatic lesions. The size of the lesion was defined as the maximal 
diameter in axial images. The readers assigned one of five 
confidence levels (Murakami et al., 2001) as follows: 0, no lesion; 1, 
probably absent; 2, possibly present; 3, probably present; 4, 
definitely present. If there were disagreements, they discussed or 
consulted another radiologist (with 9 years experience as a 
gastrointestinal radiologist) to get into accord. Every recorded 
lesion was compared with final result. Those lesions among the 
proved HCC lesions which were assigned a confidence level of 2 or 
greater were considered as true-positive findings. A lesion which 
was assigned a confidence level of 0 or 1 but actually was present 
was considered as a false-negative lesion.  




Table 2. Comparison of detection sensitivity of two size categories between groups of different iodine concentrations. 
 
Parameter Group HCC (no) EAP (%) LAP (%) PVP (%) 
A 37 54.1 (20/37)* 83.8 (31/37)* 51.4 (19/37) 
Lesions 2 cm or smaller 
B 49 28.6 (14/49) 55.1 (27/49) 38.8 (19/49) 
A 123 91.1 (112/123) 99.2 (122/123) 99.2 (122/123) 
Lesions larger than 2 cm 
B 109 88.1 (96/109) 100 (109/109) 99.1 (108/109) 
A 160 82.5 (132/160)* 95.6 (153/160)* 88.1 (141/160) 
Total 
B 158 69.6 (110/158) 86.1 (136/158) 80.4 (127/158) 
 
Group A = Iopamidol 370 mg I/ml group; Group B = Iopamidol 300 mg I/ml group; HCC, hepatocellular carcinoma; no, number; EAP, 
early arterial phase; LAP, late arterial phase; PVP, portal venous phase. Data given as percentages. Values in brackets were those 




Table 3. Comparison of detection sensitivity and positive predictive values of different phases. 
 
Lesions 2 cm or smaller Lesions larger than 2 cm Total lesions 
Phases 
Sensitivity (%) PPV (%) Sensitivity (%) PPV (%) Sensitivity (%) PPV (%) 
EAP 39.5 (34/86) 51.5 (34/66) 89.7 (208/232) 100 (208/208) 76.1 (242/318) 88.3 (242/274) 
LAP 67.4 (58/86) 55.8 (58/104) 99.6 (231/232) 100 (231/231) 90.9 (289/318) 86.3 (289/335) 
PVP 44.2 (38/86) 67.9 (38/56) 99.1 (230/232) 100 (230/230) 84.3 (268/318) 93.7 (268/286) 

2 15.38 3.55 39.07    25.62 9.29 
P value <0.01 >0.05 <0.01    <0.01 <0.01 
 
EAP, Early arterial phase; LAP, late arterial phase; PVP, portal venous phase; PPV, positive predictive value.  , we did not compare it 






Software SPSS 13.0 was used to analyze the results. The detection 
sensitivity for tumors of two iodine concentration groups for EAP, 
LAP and PVP was compared with 2 × 2 Chi-square test. 
Comparison of detection sensitivity and positive predictive values of 
different phases was tested by R×2 Chi-square test. If p value 





It was shown that there were 318 HCCs in the 94 
patients. Their sizes were from 0.6 to 25.0 cm (mean size 
5.2 cm).There were 86 tumors 2 cm and 232 tumors >2 
cm.  
Comparison of detection sensitivity of two size 
categories (2 or >2 cm) between groups of different 
iodine concentrations (370 mg /ml versus 300 mg /ml) is 
shown in Table 2. For tumors 2 cm, Iopamidol 370 mg 
/ml group (group A) showed significantly superior 
sensitivity compared to Iopamidol 300 mg /ml group 
(group B) for EAP and LAP. For tumors >2 cm, the 
detection sensitivity had no significant difference between 
two groups for all phases. Over all of the 318 tumors, the 
detection sensitivity of Iopamidol 370 mg /ml group 
(group A) was higher than Iopamidol 300 mg /ml group 
(group B) for EAP and LAP, but there was no significant 
difference between two groups for PVP. 
The comparison of detection sensitivity and positive 
predictive values of different phases is shown in Table 3. 
For tumors 2 cm, tumors >2cm and all tumors, the 
detection sensitivity showed significant differences 
between phases and the sensitivity of LAP was the 
highest. For all the tumors, the positive predictive values 
were 88.3, 86.3, 93.7% for EAP, LAP and PVP, respec-
tively, which showed significant differences between phases 





During contrast-enhanced CT, detection of HCC depends 
on several patient dependent factors including cardiac 
output, body weight, the vascularity of HCC and technology 
dependent factors, such as the scanning technique and 
the contrast injection protocol (Iannaccone et al., 2005; 
Breen et al., 2004; Kudo, 2002). These factors can 
change the time, concentration and the peak time of 
contrast agent flowing into tumor. The effects of contrast 
material dose, flow rate, iodine concentration of contrast 
material and timing had been studied in helical CT 
(Heiken et al., 1995; Hänninen et al., 2000; Kormano et 
al., 1983; Kim et al., 1998; Furuta et al., 2004; Marchianò 
et al., 2005; Behrendt et al., 2008; Sultana et al., 2003; 
Herman, 2004), but there were few researches that 
reported on the effect of iodine concentration  of  contrast  




material in which double-arterial phase scanning was 
used for  detection of HCC (Pozzi et al., 2006; Awai et al., 
2002; Yagyu et al., 2005). In 2002, Awai et al. (2002) 
evaluated the impact of contrast concentration on 
hypervascular HCC conspicuity with same iodine load per 
body weight (518 mg/kg) and concluded that the higher 
concentration may be more efficacious for imaging of 
HCC during the arterial phase on the basis of contrast 
materials with higher iodine concentration which could 
improve tumor-to-liver contrast in the first arterial phase. 
Yagyu et al. (2005) made a similar research but used a 
fixed dose of 100 ml and concluded that contrast 
materials with higher iodine concentration are more 
effective for depicting hypervascular HCCs on MSCT 
during the late arterial phase. But there were opposite 
view points on the effect of iodine concentration of 
contrast material. In 2008, Behrendt et al. (2008) published 
one study and the conclusion was that the iodine 
concentration of contrast media did not significantly 
influence abdominal contrast enhancement. Awai et al. 
(2004) even concluded that moderate concentration of 
contrast material was more effective for depiction of 
hypervascular HCC than was for high concentration of 
contrast material. Can high-iodine-concentration contrast 
material really improve the sensitivity on detection of 
HCC? Pozzi et al. (2006) used high-iodine-concentration 
contrast agent in MSCT with double-arterial phase to 
detect HCC, and got a higher sensitivity than that reported 
by others. For that reason, they thought that the high-
iodine-concentration may improve identification of HCC. 
But their results had no control group to be compared 
with and their conclusion had no statistical analysis to be 
based on. So we compared two contrast materials of 
different iodine concentration (370 and 300 mg/ml) to 
evaluate it by comparing the detection sensitivity of two 
iodine concentration groups, a methodology which was 
different from previous studies (Heiken et al., 1995; 
Hänninen et al., 2000; Kormano et al., 1983; Kim et al., 
1998; Furuta et al., 2004; Marchianò et al., 2005; Behrendt 
et al., 2008; Sultana et al., 2003; Herman, 2004; Awai et 
al., 2002, 2004; Yagyu et al., 2005). Though we thought it 
is a qualitative method, yet this method could directly 
show the impact of iodine concentration on detection 
sensitivity of HCC. For excluding the impact of the dose 
and flow rate of contrast material, Iopamidol 370 mg/ml 
(1.5 ml/kg body weight) at a flow rate of 4 ml/s and 
Iopamidol 300 mg/ml (1.85 ml/kg body weight) at a flow 
rate of 4.9 ml/s were, respectively, used to keep the total 
iodine dose (555 mg/kg body weight) and the iodine 
delivery rate (1.48 versus 1.47 g/s) constant for both 
protocols. Our results proved that for tumors 2 cm and 
all the tumors, Iopamidol 370 mg/ml group showed 
significantly superior sensitivity compared to Iopamidol 
300 mg /ml group for EAP and LAP. This may be 
explained by the reason that high-concentration contrast 
material administered leads to an earlier and more 





enhancement of tumor-to- liver, and helping improve 
diagnostic accuracy for HCC, which had  been  proved  in 
previous studies (Marchianò et al., 2005; Sultana et al., 
2003; Herman, 2004; Yagyu et al., 2005). Although the 
sensitivity of Iopamidol 370 mg/ml group was higher than 
that of Iopamidol 300 mg I/ml group for PVP, there was 
no statistical difference. Our study showed that the 
detection sensitivity of small HCC nodules was all low for 
EAP (39.5%), LAP (67.4%) and PVP (44.2%). Therefore, 
contrast material of higher iodine concentration is 
recommended for tumors 2 cm. But for tumors >2 cm, 
there was no difference between the two groups. We 
attributed this to the fact that the tumor is large, so it can 
be clearly demonstrated and easy to be found. We 
suggested that if you are sure the tumor is bigger than 2 
cm, contrast material of normal iodine concentration is 
the optimal choice. Otherwise, contrast material of high 
iodine concentration is recommended. 
Since it has been recognized that the double-arterial 
phase scanning can improve the detection sensitivity of 
HCC (Murakami et al., 2001, 2003,2005; Pozzi et al., 
2006; Schima et al., 2006; Ichikawa et al., 2002; Kajiya et 
al., 2005; Zhao et al., 2003, 2004), we did not compare it. 
We analyzed the sensitivity of the three phases, and the 
LAP was the highest. It was inconsistent with the 
researches of Foley et al. (2000), who reported that 
hepatic hypervascular tumors could be identified and 
evaluated more easily during LAP. We think it is because 
of the time needed for the contrast-filled arterial blood 
coming from the hepatic artery to spread within the lesion 
cavity. 
For the tumors of 2 cm or smaller, the positive predictive 
values of different phases were not all satisfactory (51.5 - 
57.5%). Nearly half of the lesions were misdiagnosed. 
These lesions could be often vascular pseudo lesions 
due to arterioportal shunting or tiny hemangiomas, but it 
was sometimes difficult to determine not being an HCC. 
To HCC bigger than 2 cm, the positive predictive value of 
different phase were all 100%, therefore, it can be con-
sidered that the bigger HCC cannot be left out in double-
arterial phase CT scan. To all the tumors, there were 
significant differences between different phases in positive 
predictive values and PVP had the highest positive 
predictive values (93.7%). 
There are some limitations to the study. First, double 
hepatic arterial scans would increase radiation dose. But 
for improving the detection sensitivity of HCC which had 
been reported (Murakami et al., 2001, 2003, 2005; Pozzi 
et al., 2006; Schima et al., 2006; Ichikawa et al., 2002; 
Kajiya et al., 2005; Zhao et al., 2003, 2004), this method 
is probably justifiable. Second, it was a parallel group 
study. The differences between the results of two groups 
may be attributable to the bias of the patient. However, 
we analyzed the two different groups separately and 
evaluated statistical differences between them in terms of 
demographic data, and baseline liver disease charac-





statistical differences in background factors, which made 
this possibility unlikely. Third, part of the lesions had no 
pathological confirmation. However, these lesions had 
confirmatory imaging examinations including CT and 
followed for a minimum of 6 months by several follow-up 
methods including ultrasound, contrast-enhanced CT and 
magnetic resonance imaging (MRI) which constituted 
good evidence of HCC.  
In conclusion, high-iodine-concentration contrast material 
could improve the detection of HCC for EAP and LAP, 
and is recommended for tumors 2 cm in multiphasic 
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